Please check your internet connection and try again.
# Calcium Acetate
## Overview
Calcium acetate is a phosphate binder used to manage hyperphosphatemia in patients with end-stage renal disease (ESRD). It provides higher elemental calcium content per weight and greater phosphate-binding capacity than calcium carbonate, with less pH-dependency for dissolution.
## Primary Indications
* Reduction of serum phosphorus in patients with end-stage renal disease (ESRD).
## Adult Dosing
* **Initial Dose:** 667 mg to 1334 mg (1 to 2 capsules/tablets) orally with each meal.
* **Maintenance:** Titrate based on serum phosphate levels; often 2 to 4 capsules per meal.
* **Maximum:** Generally not to exceed 12 capsules/tablets per day unless directed by a nephrologist; clinical practice varies by local institutional protocols regarding titration goals (typically targeting serum phosphorus < 5.5 mg/dL).
## Pediatric Dosing
* **Safety/Efficacy:** Not well-established in pediatric patients.
* **Dosing:** If used, dosing is off-label and must be determined by a pediatric nephrologist based on phosphate binders’ efficacy and calcium load considerations.
## Dose Adjustments
* **Renal Impairment:** Dosing is intrinsic to ESRD management; however, reduce or hold if hypercalcemia develops (>10.5 mg/dL or >11.5 mg/dL depending on institutional guidelines).
## Contraindications
* Hypercalcemia.
* Hypercalciuria.
* Hypophosphatemia.
* Nephrolithiasis.
## Adverse Effects
* **Common:** Hypercalcemia, nausea, vomiting, constipation, abdominal pain.
* **Serious:** Metastatic calcification (vascular or soft tissue), cardiac arrhythmias.
## Key Drug Interactions
* **Tetracycline/Quinolone Antibiotics:** Decreased absorption; separate administration by at least 2 hours.
* **Levothyroxine:** Decreased absorption; separate administration by at least 4 hours.
* **Bisphosphonates:** Decreased absorption; avoid concurrent administration.
* **Calcium Channel Blockers:** Potential for decreased efficacy of the CCB due to hypercalcemia.
## Monitoring
* **Serum Phosphorus:** Monitor weekly during initiation/titration, then routinely (e.g., monthly).
* **Serum Calcium:** Monitor weekly initially; watch for signs of hypercalcemia (confusion, weakness, cardiac rhythm changes).
* **Calcium-Phosphorus Product (Ca x P):** Aim to maintain < 55 mg²/dL² to minimize risks of soft tissue calcification.
## Clinical Pearls
* **Timing:** Must be taken **with meals** to effectively bind dietary phosphorus. Taking without food does little to lower phosphate and increases the risk of hypercalcemia.
* **Elemental Calcium:** 667 mg of calcium acetate contains 169 mg (approx. 25%) of elemental calcium.
* **Hypercalcemia Risk:** Patients on concomitant Vitamin D therapy or high-calcium dialysate are at higher risk for hypercalcemia.
* **Compliance:** Frequently limited by the high pill burden; consider patient adherence when assessing efficacy.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify dosages, contraindications, and drug interactions against current institutional protocols and the manufacturer’s package insert before prescribing or administering medication.*
